drugset / Trial / NCT06385678
A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety, tolerability, and efficacy of HRS-4642 in combination with antitumor medicine in patients with advanced solid tumors harboring KRAS G12D mutation.
Timeline
- Start
- 2024-07-05
- Primary completion
- 2025-12
- Completion
- 2026-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebrelimab | Monoclonal antibody | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | HRS-4642 | Unknown | — | — |
| Subject | SHR-9839 | Unknown | — | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | Pemetrexed | Small molecule | — | — |
Indications
No indication recorded.